Anti-inflammatory effects of Z-Ligustilide nanoemulsion

Inflammation

Volumn 36, Issue 2, 2013, Pages 294-299

  Ma, Zhaoji ^a   Bai, Lunhao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

bioavailability; inflammatory cells; inflammatory mediators; nanoemulsions; Z ligustilide

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; LIGUSTILIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR ALPHA; VASCULOTROPIN; Z LIGUSTILIDE;

ANGELICA SINENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PROTEIN BLOOD LEVEL; RAT; UVEITIS; ZETA POTENTIAL;

4-BUTYROLACTONE; ANGELICA SINENSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; EMULSIONS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; NANOPARTICLES; PLANT OILS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84879505583     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9546-2     Document Type: Article

References (27)

1. Huang, Y.L.; J.Y. Sheu, and T.H. Lin. 1999. Association between oxidative stress and changes of trace elements in patients with breast cancer. Clinical Biochemistry 32: 131-136.
2. Devi, G.S.; M.H. Prasad, I. Saraswathi, et al. 2000. Free radicals, antioxidant enzymes and lipid peroxidation in different types of leukemias. Clinica Chimica Acta 293: 53-62.
3. Butterfield, D.A.; B. Howard, S. Yatin, et al. 1999. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sciences 65: 1883-1892.
4. Steinbrecher, U.P.; H. Zhang, and M. Lougheed. 1990. Role of oxidatively modified LDL in atherosclerosis. Free Radical Biol. Med 9: 155-168.
5. Jira, W.; G. Spiteller, and A. Richter. 1997. Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chemistry and Physics of Lipids 87: 81-89.
6. Solans, C.; P. Izquierdo, J. Nolla, N. Azemar, and M.J. Garcia-Celma. 2005. Nano-emulsions. Current Opinion in Colloid & Interface Science 10: 102-110.
7. Tadros, T.; R. Izquierdo, J. Esquena, and C. Solans. 2004. Formation and stability of nano-emulsions. Advance Opinion in Colloid & Interface Science 108-09: 303-318.
8. Sonneville-Aubrun, O.; J.T. Simonnet, and F. L'Alloret. 2004. Nanoemulsions: a new vehicle for skincare products. Adv Opin Colloid Interface Sci 108-109: 145-149.
9. Nohynek, G.J.; J. Lademann, C. Ribaud, and M.S. Roberts. 2007. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Critical Reviews in Toxicology 37: 251-277.
10. Kuang, X.; Y. Yao, J.R. Du, Y.X. Liu, C.Y. Wang, and Z.M. Qian. 2006. Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice. Brain Research 1102: 145-153.
11. Yu, Y.; J.R. Du, C.Y. Wang, and Z.M. Qian. 2008. Protection against hydrogen peroxide-induced injury by Z-ligustilide in PC12 cells. Experimental Brain Research 184(3): 307-312.
12. Du, J.; Y. Yu, Y. Ke, C. Wang, L. Zhu, and Z.M. Qian. 2007. Ligustilide attenuates pain behavior induced by acetic acid or formalin. Journal of Ethnopharmacology 112: 211-214.
13. Miguel, F.; A. Martin, F. Mattea, and M.J. Cocero. 2008. Precipitation of lutein and coprecipitation of lutein and poly-lactic acid with the supercritical antisolvent process. Chemical Engineering and Processing 47: 1594-1602.
14. Yoo, J.H.; S. Shanmugam, P. Thapa, et al. 2010. Novel self-nanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Archives of Pharmacal Research 33: 417-426.
15. Balakrishnan, P.; B.J. Lee, D.H. Oh, et al. 2009. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). European Journal of Pharmaceutics and Biopharmaceutics 72: 539-545.
16. Gershanik, T.; E. Haltner, C.M. Leh, and S. Benita. 2000. Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. International Journal of Pharmaceutics 211: 29-36.
17. Wei, L.L.; P.N. Sun, S.F. Nie, and W.S. Pan. 2005. Preparation and evaluation of SEDDS and SMEDDS containing Carvedilol. Drug Development and Industrial Pharmacy 31: 785-794.
18. Xi, J.; Q. Chang, C.K. Chan, et al. 2009. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS PharmSciTech 10: 172-182.
19. Ghosh, P.K.; and R.S. Murthy. 2006. Microemulsions: a potential drug delivery system. Current Drug Delivery 3: 167-180.
20. Liu, Y.; P. Zhang, N. Feng, X. Zhang, S. Wu, and J. Zhao. 2009. Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. International Journal of Pharmaceutics 365: 136-142.
21. Patel, D.; and K.K. Sawant. 2009. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Current Drug Delivery 6: 419-424.
22. Lu, J.L.; J.C. Wang, S. Zhao, et al. 2008. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. European Journal of Pharmaceutics and Biopharmaceutics 69: 899-907.
23. Ghosh, P.K.; R.J. Majithiya, M.L. Umrethia, and R.S. Murthy. 2006. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 7: E172-E177.
24. Calcagni, E.; and I. Elenkov. 2006. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Annals of the New York Academy of Sciences 1069: 62-76.
25. Schiller, M.; D. Metze, T.A. Luger, S. Grabbe, and M. Gunzer. 2006. Immune response modifiers - mode of action. Experimental Dermatology 15: 331-341.
26. Annunziato, F.; L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani. 2008. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. International Immunology 20: 1361-1368.
27. Stow, J.L.; P. Ching Low, C. Offenhäuser, and D. Sangermani. 2009. Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiology 214: 601-614.